Introduction
============

Dementia is a broad battery of brain diseases that cause a long-term cognitive decline and is to affect a person's daily living. Alzheimer's disease (AD) is the most common cause of dementia, which is characterized by irreversible decline of memory and other cognitive domains. More than 44 million individuals are afflicted with AD nowadays, and the prevalence is expected to increase to 115.4 million by 2050.[@b1-cia-13-159] Many patients gradually lost the ability to work due to decline in cognitive abilities and finally lost the capability of physical self-maintenance in the late stage of the disease. In the People's Republic of China, many patients who are in the late stage of dementia are sent to mental disorder hospitals. In our opinion, these patients provide a very good resource to study the characteristics of dementia. However, there was no existing study about the late stage of dementia patients in the People's Republic of China. Therefore, one of our aims is to analyze the distribution of patients in the late stage of dementia through a cross-sectional investigation.

The apolipoprotein E (*APOE*) gene encodes a glycoprotein that plays an important role in central nervous system (CNS) lipid homeostasis during neuronal growth and in nerve regeneration. There are three major *APOE* isoforms: *ApoE ε2*, *ApoE ε3* and*ApoE ε4*. The *ε4* allele of *APOE* was believed to be a detrimental factor for sporadic Alzheimer's disease (SAD).[@b2-cia-13-159],[@b3-cia-13-159] It has been reported that the *ε4* allele is associated with a higher level of serum total cholesterol (TC) as well as with low-density lipoprotein cholesterol.[@b4-cia-13-159]--[@b6-cia-13-159] Besides, previous studies also found that the *ε4* allele affected cerebral glucose metabolism and resulted in increased deposition of Aβ.[@b7-cia-13-159],[@b8-cia-13-159] However, most of these studies were performed in the Caucasian population with controversial results and there has been no study about the association between the *APOE* genotype and the levels of serum biochemical parameters in the late stage of dementia in AD patients. In the current study, we analyzed the proportion of AD among these dementia patients and studied the associations of *APOE* genotypes with the levels of TC, total triglycerides (TG) and the blood glucose of the AD patients.

Methods and materials
=====================

Subjects
--------

All the patients were enrolled at the Mental Health Center of Zhejiang University School of Medicine in Hangzhou from March 2014 to July 2016. The disease duration was more than 5 years (mean 10.26 years, standard deviation 3.974 years). The Diagnostic and Statistical Manual of Mental Disorders, 4th Edition,Text Revision (DSM-IV-TR) and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria were applied to obtain the diagnosis of probable clinical AD. Moreover, the criterion[@b9-cia-13-159] for dementia with Lewy bodies (DLB), the criterion[@b10-cia-13-159] for fronto-temporal dementia (FTD) and the NINDS--AIREN criteria for vascular dementia (VaD) were applied to obtain the diagnosis of non-SAD forms of dementia.[@b9-cia-13-159]--[@b11-cia-13-159] Furthermore, the routine medical examination, neurological examination, neuroimaging tests (CT or MRI), the Mini-Mental State Examination (MMSE), the Activity of Daily Living Scale (ADL) and the Clinical Dementia Rating (CDR) were applied to evaluate each participant. The exclusion criteria were described in our previous study.[@b12-cia-13-159] Briefly, patients with depression, mental retardation and other psychiatric disorders; hydrocephalus; syphilis; cognitive disorders caused by head trauma; poisoning; Huntington's disease; and severe heart, lung or kidney disease were excluded. This study was approved by the ethics committee of the Mental Health Center of Zhejiang University School of Medicine. All participants were Han people, and written informed consents were obtained from the patients or the guardians of the patients.

Genotyping of APOE
------------------

Genomic DNA was extracted from peripheral blood using a Blood Genomic DNA Extraction Kit (Tiangen, People's Republic of China). The primer for genotyping of *APOE* included Cys158/Arg158 (5′-ATGCCGATGACCTGCAGAATT-3′/5′-ATGCCGATGACCTGCAGAATC-3′), Cys112/Arg112 (5′-CGCGGACATGGAGGACGTTT-3′)/(5′-CGCGGACATGGAGGACGTTC-3′) and a common primer (5′-GTTCAGTGATTGTCGCTGGGCA-3′). The multiplex amplification refractory mutation system polymerase chain reaction was applied to determine *APOE* genotypes.[@b13-cia-13-159]

Measurement and analysis serum levels of TC and TG
--------------------------------------------------

Serum TC, TG and fasting blood glucose levels were determined on the same auto-analyzer (Olympus, Tokyo, Japan, AU640). The serum TC level \>5.7 mmol/L, TG level \>1.8 mmol/L and fasting blood glucose \>6.1 mmol/L were defined as hypercholesterolemia, hypertriglyceridemia and hyperglycemia, respectively.

Statistical analysis
--------------------

The *APOE ε4* allele frequency and *ε4ε4* genotype were compared using the chi-square test, and the age and the MMSE scores were assessed by one-way analysis of variance in the different groups. The mean value of glucose, TC and TG were assessed by independent-samples *t*-test in the different groups. Logistic regression analyses were performed to evaluate the possible associations between *APOE* genotype and the biochemical parameters. Covariates were age, history of hypertension and history of smoking and alcohol drinking. All statistical analyses were performed by the SPSS version 15.0 software (SPSS Inc., Chicago, IL, USA). *P*-values less than 0.05 were considered statistically significant.

Results
=======

The disease distribution and APOE genotype
------------------------------------------

A total of 155 patients who were in the late stage of dementia were enrolled in this study. In our study cohort, the majority of the subjects were patients with AD, which accounted for 67.8% of total subjects. In all, 15.5% and 9% of patients had VaD and mixed dementia, respectively. The remaining 7.7% consisted of subjects with FTD, DLB and patients who were very difficult to classify. The detailed disease distribution and *APOE* genotype are shown in [Table 1](#t1-cia-13-159){ref-type="table"}. Age, sex, the ADL and the *ε4ε4* genotype did not have statistically significant differences. The MMSE scores, the CDR and the *APOE ε4* allele frequency were significantly different in the different groups.

Association between the serum levels of biochemical parameters and APOE genotypes in AD patients
------------------------------------------------------------------------------------------------

The characteristics of AD patients with different *APOE* isoforms are shown in [Table 2](#t2-cia-13-159){ref-type="table"}. The serum level of TC in *APOE ε4* carriers was higher than in non-carriers. No statistically significant differences were found in the blood glucose and TG levels between these two groups. No correlations were found between the *APOE ε4* carrier status and serum levels of glucose (adjusted odds radio 1.179, 95% confidence interval 0.334--4.168, *P*=0.798), TC (adjusted odds radio 2.028, 95% confidence interval 0.392--10.502, *P*=0.400) and TG (adjusted odds radio 1.238, 95% confidence interval 0.518--2.958, *P*=0.630). Details are shown in [Table 3](#t3-cia-13-159){ref-type="table"}.

Discussion
==========

With the increase in human lifespan, the age-related neurodegenerative diseases have become the biggest challenges of the 21st century. Dementia, including AD, is one of the most devastating neurodegenerative disorders that affect millions of people annually. In the People's Republic of China, many late-stage dementia patients are sent to mental disorder hospitals due to loss of ability of physical self-maintenance and mental confusion. In this study, we analyzed the disease distribution of patients who were in the late stage of dementia in a mental disorder hospital in Southeast China. We found that the most common type of dementia was AD (67.8%), followed by VaD (15.5%) and mixed dementia (9%), while FTD and DLB were comparatively rare in our study cohort. These results were quite consistent with previous studies. For example, researchers studied the disease distribution of 1,194 cases of dementia in patients aged above 70 years in Spanish populations and found that 707 (59.2%) had AD and 238 (19.9%) had VaD.[@b14-cia-13-159] Besides, in Italy, a prevalence study of dementia in an elderly rural population found that AD accounted for 64%, VaD for 27% and other dementia diseases for 9%.[@b15-cia-13-159] Moreover, in a meta-analysis of prevalence of dementia in developing countries, AD was reported to account for 60%, whereas VaD accounted for about 30%.[@b16-cia-13-159] Although these were all results from prevalence studies and our study was a cross-sectional study of inpatients of late-stage dementia, the results were comparable. As a result, we postulate that inpatients in the late stage of dementia are a small focus group of these disease groups, which makes it a good resource for investigating this disorder.

In our study results, the *APOE ε4* allele frequency differed significantly between the four subgroups, which was consistent with previous studies in Chinese AD patients.[@b17-cia-13-159] The *APOE* protein is believed to play an important role in CNS lipid homeostasis during neuronal growth and in nerve regeneration. Recently, one study indicated that a higher serum level of total cholesterol was associated with *APOE ε4* carriers in a cognitively normal aging population.[@b18-cia-13-159] Previous studies reported the *APOE ε4* status had an influence on the level of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol.[@b19-cia-13-159] In our study, the serum level of TC was higher in the *APOE ε4* carriers, compared with the non-*APOE ε4* carrier group. This result suggested that the *APOE* protein might be involved in a specific pathophysiologic mechanism of lipid metabolism in the development of AD.

Lately, it has been reported that dysregulation of glucose metabolism in the brain is a risk factor for mild cognitive impairment and AD.[@b20-cia-13-159],[@b21-cia-13-159] Besides, one study suggested that high serum glucose levels may worsen cognitive function as well as accelerate the cognitive decline.[@b22-cia-13-159] Some studies reported that*APOE ε4* modulates regional cerebral glucose metabolism and affects the signal of glucose and amyloid metabolic pathways in the pathogenesis of AD.[@b23-cia-13-159],[@b24-cia-13-159] Another research indicated that the mean prevalence of PET amyloid positivity is 95% in *APOE ε4*-positive AD patients.[@b25-cia-13-159] In addition, previous studies have reported that the *APOE ε3* genotype had higher glucose levels than the *APOE ε4* genotype.[@b26-cia-13-159] Furthermore, *APOE ε4* carrier status and elevated blood glucose were associated with more severe AD pathology.[@b27-cia-13-159] Overall, all these studies have demonstrated that the *APOE* protein plays an important role in the pathogenesis of late-onset AD, not only in the aspect of Aβ deposition but also in the aspect of cerebral glucose metabolism. However, in our study, we were unable to find a positive association between the level of blood glucose and *APOE* genotypes.

There are some limitations of our study. First and most important of all, the sample size was comparatively small. It will be necessary to replicate these study results in a large population. Besides, we have only analyzed some basic biochemical parameters in this current study. A further extension of these parameters, for example, the level of glucose intolerance and insulin resistance, will be more accurate and powerful.

Conclusion
==========

To the best of our knowledge, this is the first paper to study the characteristics of late-stage dementia in hospital patients in Southeast China. We found that the disease distribution was quite consistent with previous prevalence studies. Moreover, we found that the serum level of TC was higher in the *APOE ε4* carrier group. However, no association was found between the *APOE ε4* allele and serum levels of glucose, TC and TG in the late stage of AD.
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###### 

Characteristics of subjects with different kinds of dementia

  Characteristics           AD            VaD            MD            Other kinds of dementia   *P*-value
  ------------------------- ------------- -------------- ------------- ------------------------- -----------
  Number                    105           24             14            12                        
  Age (mean ± SD) (years)   79.80±8.436   79.12±11.403   80.21±3.745   75.33±11.484              NS
  Male/female               32/73         12/12          5/9           7/5                       NS
  MMSE (mean ± SD)          0.84±2.822    3.08±6.086     1.64±3.272    8.08±9.030                \<0.05
  ADL (mean ± SD)           78.46±4.635   78.50±4.065    77.36±7.602   73.42±9.239               NS
  CDR =3                    98 (93.33%)   18 (75.00%)    12 (85.71%)   7 (58.33%)                \<0.05
  *APOE ε4* carrier         65 (61.90%)   9 (37.50%)     6 (42.86%)    4 (33.33%)                \<0.05
  *APOE ε4ε4* genotype      20 (19.04%)   3 (12.5%)      0 (0%)        1 (8.33%)                 NS

**Abbreviations:** AD, Alzheimer's disease; VaD, vascular dementia; MD, mixed dementia; NS, non-significant; MMSE, Mini-Mental State Examination; ADL, Activity of Daily Living Scale; CDR, Clinical Dementia Rating; *APOE*, apolipoprotein E.

###### 

Characteristics of AD patients with different *APOE status*

  Characteristics                  Non-*APOE ε4* carrier   *APOE ε4* carrier   *P*-value
  -------------------------------- ----------------------- ------------------- -----------
  Number                           40 (38.1%)              65 (61.9%)          
  Age, years                       79.55±8.676             79.95±8.349         NS
  Sex, male/female                 13/27                   19/46               NS
  Fasting blood glucose, mmol/L    5.10±0.79               5.18±0.97           NS
  Serum triglycerides, mmol/L      1.69±0.57               1.96±1.03           NS
  Total cholesterol, mmol/L        4.21±0.94               4.62±1.01           *P*=0.037
  Hypertension                     27                      40                  NS
  Alcohol users (\>1 drink/week)   4                       7                   NS
  Cigarette smoking                4                       6                   NS

**Notes:** *APOE* genotypes: *ε2/2* or *ε2/3* or *ε3/3* (non-*APOE ε4* carrier); *ε2/4, ε3/4*, or *ε4/4* (*APOE ε4* carrier).

**Abbreviations:** AD, Alzheimer's disease; *APOE*, apolipoprotein E; NS, non-significant.

###### 

Effects of *APOE ε4* allele on biochemical parameters

  Biochemical parameters   OR      95% CI          *P*-value
  ------------------------ ------- --------------- -----------
  Blood glucose            1.179   0.334--4.168    0.798
  Total cholesterol        2.028   0.392--10.502   0.400
  Total triglycerides      1.238   0.518--2.958    0.630

**Note:** Logistic regression model was adjusted for age, history of hypertension, alcohol use and smoking use.

**Abbreviations:** *APOE*, apolipoprotein E; OR, odds ratio; CI, confidence interval.
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